BIOCRYST PHARMACEUTICALS INC — Director's Dealing 2015

Jun 16, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK: 0000882796
Period of Report: 2015-05-13

Reporting Person: Stonehouse Jon P (Director, President & CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2015-05-13	Emp. Stock Option (Right to Buy)	$5.45	A	25000	Acquired	2023-08-08	Common Stock (25000)	Direct

Footnotes

F1: On May 13, 2015, BioCryst Pharmaceuticals, Inc. initiated a Phase 1 clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of orally-administered BCX7353 in healthy volunteers. As a result, one of the vesting criteria associated with the performance-based stock options awarded to all employees in August 2013 has been met. Therefore, 25% of the performance-based stock options vested on May 13, 2015.